13 results about "Elisa assay" patented technology

This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting feline NT-proBNP protein and its applications. The monoclonal antibody combination of the present invention comprises monoclonal antibodies 3A6 and 5H5. These two antibodies possess unique heavy and light chain variable region complementarity-determining regions, respectively, and their amino acid sequences have been fully defined (SEQ ID NOs. 1-12). This antibody combination can specifically recognize and efficiently bind to feline NT-proBNP protein, making it suitable for the development of a highly sensitive and specific diagnostic tool for feline cardiomyopathy. By constructing a double-antibody sandwich ELISA assay system, the minimum detection limit can reach 100 pg / mL, and it exhibits excellent specificity and stability.

This invention discloses an antibody that specifically recognizes Toxoplasma gondii surface antigens and its applications. The invention utilizes hybridoma technology to establish a hybridoma cell line by fusing Balb / C mouse spleen cells with SP2 / 0 cells. Monoclonal antibodies were prepared from these cells using in vitro culture and in vivo ascites induction methods, yielding the monoclonal antibody SH12-S7. This invention provides clinical and research institutions with an antibody that specifically recognizes Toxoplasma gondii surface antigens. It can be used for ELISA assays to detect clinical samples, for immunohistochemical assays to diagnose pathological specimens, and provides a convenient research tool for toxoplasmosis research departments. It has broad application value in the diagnosis and detection of definitive host infections and provides technical support for epidemiological investigations and evaluation of control effects of Toxoplasma gondii.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, YKKLHK(162860), was artificially synthesized in a solid phase. Using artificially expressed PEDV Nsp5 protein, the peptide was screened using an ELISA assay. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 162860 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 162860 sequence significantly inhibited PEDV infection.

Immunoglobulin light Chain "AL" amyloidosis is the most common form of systemic amyloidosis, accounting for approximately 70% of the diagnosed cases in developed countries. As there are treatments available, e.g., based on antibody C11-1F4, and in development for AL amyloidosis, there is a need in for more accurate methods for quality control of c11-1F4 antibodies or antigen-binding fragment thereof. Immunoassays, methods, and kits for testing the specificity of 11-1F4 antibodies are provided. The immunoassays, methods, and kits are more than 10 times more sensitive than the ELISA protocol that is routinely used for evaluation of c11-1F4 binding to LEN peptide.

The invention provides an ELISA (Enzyme-Linked Immunosorbent Assay) detection method of an anti-CD3 antibody. The detection method provided by the invention can accurately detect the anti-CD3 antibody impurity in the cell preparation product, avoids the medication risk, and is beneficial to improving the safety of the cell preparation product.

Methods, systems, and kits are provided for standardizing lectin reagents and measuring galactose-deficient IgA1 (Gd-IgA1) as a biomarker for IgA nephropathy. The invention includes a method for standardizing test batches of lectin reagents by comparing binding activity to reference batches using calibration standards, with acceptance criteria based on analytical recovery within thresholds. A stabilized reference standard comprising enzymatically modified or recombinantly produced Gd-IgA1 exhibits parallelism with natural serum samples and enables reproducible quantification across runs. The invention further provides a lectin-based ELISA assay kit for quantitative measurement of Gd-IgA1 in biological samples, particularly serum, using standardized N-acetylgalactosamine (GalNAc)-specific lectins such as biotinylated Helix pomatia agglutinin (HPA) or Helix aspersa agglutinin (HAA). Clinical applications include diagnosing IgA nephropathy, risk stratification, monitoring disease progression, assessing treatment response, and screening kidney transplant donors. The standardization methodology is broadly applicable to validating binding reagents for detecting diverse biomarkers, peptides, and proteins in diagnostic assays.

Immunoglobulin light Chain “AL” amyloidosis is the most common form of systemic amyloidosis, accounting for approximately 70% of the diagnosed cases in developed countries. As there are treatments available, e.g., based on antibody C11-1F4, and in development for AL amyloidosis, there is a need in for more accurate methods for quality control of c11-1F4 antibodies or antigen-binding fragment thereof. Immunoassays, methods, and kits for testing the specificity of 11-1F4 antibodies are provided. The immunoassays, methods, and kits are more than 10 times more sensitive than the ELISA protocol that is routinely used for evaluation of c11-1F4 binding to LEN peptide.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

The invention relates to detection of the cellular immune level of a Brucella vaccine, in particular to an antibody and a kit for detecting specific gamma interferon generated by immunizing cattle with the Brucella vaccine. The invention provides an antibody pair for detecting bovine gamma interferon through a double-antibody sandwich enzyme-linked immunosorbent assay. The antibody pair consists of a capture antibody and a detection antibody, the capture antibody is secreted by a hybridoma cell with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.45838; the detection antibody is secreted by a hybridoma cell with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.46325. The bovine gamma interferon ELISA detection method established based on the antibody pair has the advantages of high sensitivity, strong specificity and good repeatability, and can be used for detecting the production level of specific gamma interferon of Brucella vaccine immunized cattle so as to evaluate the cellular immune level of an organism.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat NT-proBNP protein and application of the monoclonal antibody combination. The monoclonal antibody combination provided by the invention comprises a monoclonal antibody 3A6 and a monoclonal antibody 5H5. The two antibodies respectively have unique heavy chain and light chain variable region complementarity determining regions, and the amino acid sequences of the two antibodies are defined in detail (SEQ ID NO.1-12). The antibody combination can specifically recognize and efficiently bind the cat NT-proBNP protein, and is suitable for developing a high-sensitivity and high-specificity diagnostic tool for cat cardiomyopathy. By constructing a double-antibody sandwich ELISA detection system, the lowest detection limit can reach 100 pg / mL, and good specificity and stability are shown.

The invention belongs to the technical field of biological medicine, and particularly relates to an anti-JAML antibody and application thereof in tumor treatment. Specifically, a Fab antibody fragment specifically bound with a target antigen and a cell is enriched in a solid phase, liquid phase and cell sea selection mode; different output sets are detected by an ELISA experimental method, ELISA preliminary screening is carried out, specifically-bound positive clones are obtained, finally, the anti-JAML monoclonal antibody is obtained, the binding activity of the anti-JAML monoclonal antibody is high, meanwhile, tests verify that the anti-JAML monoclonal antibody has good anti-tumor activity, and therefore the anti-JAML monoclonal antibody is beneficial to basic research and clinical experiments, has the potential for preventing and treating cancers and has good application prospects. Therefore, the method has good practical application value.

The present disclosure describes anti-Miro1 polypeptides or binding fragments thereof, and nucleic acids, compositions, methods, kits, and systems related to the polypeptides or binding fragments. In one aspect, the anti-Miro1 polypeptides or binding fragments thereof can be used as capture and detection reagents in a Miro1 ELISA assay. The Miro1 ELISA assay as described herein is capable of selective detection of Miro1 protein over Miro2 protein.

Methods, systems, and kits are provided for standardizing lectin reagents and measuring galactose- deficient IgAl (Gd-IgAl) as a biomarker for IgA nephropathy. The invention includes a method for standardizing test batches of lectin reagents by comparing binding activity to reference batches using calibration standards, with acceptance criteria based on analytical recovery within thresholds. A stabilized reference standard comprising enzymatically modified or recombinantly produced Gd-IgAl exhibits parallelism with natural serum samples and enables reproducible quantification across runs. The invention further provides a lectin-based ELISA assay kit for quantitative measurement of Gd-IgAl in biological samples, particularly serum, using standardized N-acetylgalactosamine (GalNAc)-specific lectins such as biotinylated Helix pomatia agglutinin (HP A) or Helix aspersa agglutinin (HAA). Clinical applications include diagnosing IgA nephropathy, risk stratification, monitoring disease progression, assessing treatment response, and screening kidney transplant donors. The standardization methodology is broadly applicable to validating binding reagents for detecting diverse biomarkers, peptides, and proteins in diagnostic assays.